Revenio Group Oyj 最近的每股盈餘為 $0.2,{eisBeating} $0.25 的預期。
Revenio Group Oyj REVXF 上一季度的收入表現如何?
Revenio Group Oyj 上一季度的收入為 $0.2
Revenio Group Oyj 的收入預期是多少?
根據 7 位華爾街分析師的預測,Revenio Group Oyj 的收入預期範圍從 $29.4M 到 $26.46M
Revenio Group Oyj 的盈利品質評分是多少?
Revenio Group Oyj 的盈利品質評分為 /。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Revenio Group Oyj 何時發布財報?
Revenio Group Oyj 的下一份財報預計在 2026-05-12 發布
Revenio Group Oyj 的預期收益是多少?
根據華爾街分析師的預測,Revenio Group Oyj 的預期收益為 $33.04M
Revenio Group Oyj 是否超出收益預期?
Revenio Group Oyj 最近的收益為 $31.2M,未達預期 預期。
關鍵數據
前收市價
$25
開盤價
$25
當日範圍
$25 - $25
52週區間
$25 - $31.47
交易量
100
平均成交量
0
股息收益率
--
每股盈餘 (TTM)
0.78
市值
$667.0M
什麼是 REVENIO GROUP OYJ?
Revenio Group Oyj engages in ophthalmic diagnostics and the manufacture and sale of ophthalmic devices. The company is headquartered in Vantaa, Etela-Suomen and currently employs 247 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.